Compare Gilead Sciences, Inc. (GILD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Mesoblast Limited — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Mesoblast Limited trades at $19.22 (market cap $2.31B). The key difference: Gilead Sciences, Inc. is far larger — about 70.8× Mesoblast Limited's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GILD | MESO | |
|---|---|---|
Market Cap | $163.51B | $2.31B |
Sector | Health | Technology |
52-Week High | $155.80 | $20.96 |
52-Week Low | $108.22 | $11.35 |
Enterprise Value | $178.05B | $2.32B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
